MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer
Abstract Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer that rarely develops de novo in primary tumors and is commonly acquired during the development of treatment resistance. NEPC is characterized by gain of neuroendocrine markers and loss of androgen receptor (AR), ma...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Nature Portfolio
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/0691e54f4cb8403ba947ac009a53d0a8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|